Forum Replies Created
Viewing 1 reply thread
- Replies
-
-
- April 8, 2021 at 6:31 pm
Thanks so much for your helpful reply. It looks like TAVO + pembro may be more promising than T-VEC + pembro because of the demonstrated benefit (in KEYNOTE-695) in patients with anti-PD-1 checkpoint resistance. I wonder if it would be worth looking into the possibility of expanded access for TAVO + pembro? Does anyone on the forum have experience with expanded access?